Product Details
| Product Name: Amikacin Disulfate | CAS No.: 39831-55-5 |
| EC-No.: 254-648-6 | Min. Order: 6.5kg |
| Purity: 1:1.8 salt; 691-806 μg/mg; Sterile; USP | Supply Ability: 10 TONS |
| Release date: 2026/02/09 | |
| Type: SZ01 |
Amikacin Disulfate Cas 39831-55-5
Specification
Items |
Specification |
Result |
Appearance | White crystalline powder | Complies |
Assay | 691-806 μg/mg | 749μg/mg |
Loss on drying | ≤13% | 4.65% |
Residue on ignition | ≤1.0% | 0.07% |
Sterility | Should meet the requirement | Complies |
Welcome to contact with us to get more information.
Amikacin Disulfate is a salt form of the antibiotic amikacin, specifically where the amikacin base is combined with two sulfate groups. It is a semi-synthetic aminoglycoside antibiotic derived from kanamycin A.
Primary Uses:
Amikacin disulfate is a potent, broad-spectrum antibiotic used almost exclusively in hospital settings for serious, often life-threatening infections, particularly those caused by Gram-negative bacteria. Its major uses include:
Treatment of Resistant Infections: It is a key drug for infections resistant to other aminoglycosides (like gentamicin or tobramycin) and other antibiotics, due to its stability against many bacterial-inactivating enzymes.
Gram-Negative Bacilli Infections: Used for severe infections caused by bacteria such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella, and Acinetobacter. Common infection sites include:
Complex urinary tract infections
Bloodstream infections (sepsis)
Pneumonia (especially hospital-acquired/ventilator-associated)
Post-surgical or intra-abdominal infections
Mycobacterial Infections: It is a second-line drug in the treatment of multidrug-resistant tuberculosis (MDR-TB).
Combination Therapy: Often used in combination with a beta-lactam antibiotic (like a penicillin or cephalosporin) for synergistic effect and to broaden coverage, especially in febrile neutropenia or empirical treatment of severe sepsis.
Key Administration & Safety Notes:
Route: Administered only by intravenous (IV) infusion or intramuscular (IM) injection.
Critical Monitoring: Requires careful therapeutic drug monitoring (measuring peak and trough blood levels) due to its narrow therapeutic index.
Major Toxicities: The two main dose-limiting side effects are:
Nephrotoxicity (kidney damage)
Ototoxicity (irreversible damage to the inner ear, leading to hearing loss and/or balance disturbances).
In summary, amikacin disulfate is a powerful, last-line injectable antibiotic reserved for severe, resistant bacterial infections in controlled hospital settings, where its benefits are weighed against significant potential toxicity.
Packages

Delivery

Payment term
* Wire Transfer/Telegraphic Transfer
* Western Union
* MoneyGram
* L/C
Contact information
Spring Zhang
Email: export@fortunachem.com
Skype: Fortunachem201304
Wechat/Whatsapp: 18007136271
Tel: +86-27-59207892
Website: www.fortunachem.com
Company Profile Introduction
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $42.00/500mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-01-19 | |
| $0.00/1kg |
VIP1Y
|
Hefei Lbao Physical & Chemical Science Co.,Ltd
|
2025-11-19 | |
| $50.00/1KG |
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2025-09-03 | |
| $/ |
VIP5Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | |
| $10.00/1KG |
Shandong Xuhuang New material CoLTD
|
2025-02-25 | ||
| $0.00/1KG |
VIP7Y
|
Hebei Chuanghai Biotechnology Co., Ltd
|
2024-12-09 | |
| $1.90/1KG |
VIP5Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-14 | |
| $0.00/1kg |
VIP2Y
|
Hangzhou Hyper Chemicals Limited
|
2024-07-03 | |
| $0.00/1kg |
VIP2Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2024-05-13 | |
| $20.00/1kg |
Hebei Kangcang new material Technology Co., LTD
|
2024-04-25 |
- Since: 2006-04-03
- Address: Room 2015, No.2 Building Kaixin Mansion, No.107 Jinqiao Ave, Wuhan, China
+8613986145403
info@fortunachem.com

China